(Q37136996)

18 August 2017

1 reference

title

Capecitabine in the treatment of advanced gastric cancer (English)

1 reference

18 August 2017

1 reference

Jae-Lyun Lee

1

1 reference

18 August 2017

Yoon-Koo Kang

series ordinal

2

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 April 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

4

1 reference

18 August 2017

issue

2

1 reference

18 August 2017

page(s)

179-198

1 reference

Global cancer statistics, 2002

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Epidemiology of upper gastrointestinal malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: report from the Japan Clinical Oncology Group (JCOG).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: A Phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Capecitabine: preclinical pharmacology studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Antitumor activity of combinations of anti-HER-2 antibody trastuzumab and oral fluoropyrimidines capecitabine/5'-dFUrd in human breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5'-deoxy-5-fluorouridine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Clinical pharmacokinetics of capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Cellular pharmacology of fluorinated pyrimidines in vivo in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Preliminary studies of a novel oral fluoropyrimidine carbamate: capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Gastric Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Phase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Progress in colorectal cancer chemotherapy: how far have we come, how far to go?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Cellular and molecular aspects of drugs of the future: oxaliplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

A molecular biological study of anti-tumor mechanisms of an anti-cancer agent Oxaliplatin against established human gastric cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Capecitabine (Xeloda) in combination with oxaliplatin: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Thalidomide use and digital gangrene

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Hexamethylmelamine and Low or Moderate Dose Cisplatin With or Without Pyridoxine for Treatment of Advanced Ovarian Carcinoma: A Study of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Acute coronary syndrome induced by oral capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Coronary spasm induced by capecitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Capecitabine induces severe angina-like chest pain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Capecitabine as adjuvant treatment for stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

A phase I study of S-1 combined with weekly cisplatin for metastatic gastric cancer in an outpatient setting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.4.2.179

21 January 2018

Identifiers

DOI

10.2217/14796694.4.2.179

1 reference

18 August 2017

1 reference